Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Down 85.2% in June

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 33,404 shares, a decline of 85.2% from the May 31st total of 225,674 shares. Based on an average trading volume of 313,931 shares, the short-interest ratio is currently 0.1 days. Approximately 6.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter worth approximately $124,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at $37,000. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at $26,000. Finally, Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at $357,000. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Stock Performance

NASDAQ SHPH opened at $3.78 on Friday. Shuttle Pharmaceuticals has a one year low of $3.16 and a one year high of $55.90. The stock has a 50-day moving average of $6.44 and a 200 day moving average of $11.15. The company has a market capitalization of $2.42 million, a price-to-earnings ratio of -0.08 and a beta of 0.18.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .